These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 32693665)

  • 21. COVID-19 vaccines: rapid development, implications, challenges and future prospects.
    Kashte S; Gulbake A; El-Amin Iii SF; Gupta A
    Hum Cell; 2021 May; 34(3):711-733. PubMed ID: 33677814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. With Great Hopes Come Great Expectations: Access and Adoption Issues Associated With COVID-19 Vaccines.
    Su Z; McDonnell D; Cheshmehzangi A; Li X; Maestro D; Šegalo S; Ahmad J; Hao X
    JMIR Public Health Surveill; 2021 Aug; 7(8):e26111. PubMed ID: 33560997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases.
    MacPherson A; Hutchinson N; Schneider O; Oliviero E; Feldhake E; Ouimet C; Sheng J; Awan F; Wang C; Papenburg J; Basta NE; Kimmelman J
    Ann Intern Med; 2021 Mar; 174(3):326-334. PubMed ID: 33226855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coronavirus Vaccine: Light at the End of the Tunnel.
    Ella KM; Mohan VK
    Indian Pediatr; 2020 May; 57(5):407-410. PubMed ID: 32291382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 vaccines: ethical framework concerning human challenge studies.
    Calina D; Hartung T; Docea AO; Spandidos DA; Egorov AM; Shtilman MI; Carvalho F; Tsatsakis A
    Daru; 2020 Dec; 28(2):807-812. PubMed ID: 32851596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations.
    Sultana J; Mazzaglia G; Luxi N; Cancellieri A; Capuano A; Ferrajolo C; de Waure C; Ferlazzo G; Trifirò G
    Expert Rev Vaccines; 2020 Oct; 19(10):919-936. PubMed ID: 32940090
    [No Abstract]   [Full Text] [Related]  

  • 28. Elimination could be the optimal response strategy for covid-19 and other emerging pandemic diseases.
    Baker MG; Wilson N; Blakely T
    BMJ; 2020 Dec; 371():m4907. PubMed ID: 33561814
    [No Abstract]   [Full Text] [Related]  

  • 29. Covid-19 and non-communicable diseases (NCDs) in Africa: a narrative review.
    Olanrewaju YA; Oladunni AA; David KB; Babatunde YO; Damilola IA; Adedeji O; Ahamefula CC
    Afr Health Sci; 2023 Sep; 23(3):412-421. PubMed ID: 38357149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lockdown is an effective 'vaccine' against COVID-19: A message from India.
    Krishan K; Kanchan T
    J Infect Dev Ctries; 2020 Jun; 14(6):545-546. PubMed ID: 32683342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coronavirus (COVID-19) Pandemic in Nigeria: Preventive and Control Challenges within the First Two Months of Outbreak.
    Omaka-Amari LN; Aleke CO; Obande-Ogbuinya NE; Ngwakwe PC; Nwankwo O; Afoke EN
    Afr J Reprod Health; 2020 Jun; 24(s1):87-97. PubMed ID: 34077058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Herd immunity: challenges and the way forward in Korea.
    Oh J; Kim S; Ryu B; Shin M; Kim BI
    Epidemiol Health; 2021; 43():e2021054. PubMed ID: 34412446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Access considerations for a COVID-19 vaccine for South Africa.
    Bangalee V; Suleman F
    S Afr Fam Pract (2004); 2020 Oct; 62(1):e1-e4. PubMed ID: 33179954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acceptance of a COVID-19 Vaccine Before it is Available in China During the Pandemic.
    Xu J; Liu C
    Int J Public Health; 2021; 66():1604092. PubMed ID: 34744597
    [No Abstract]   [Full Text] [Related]  

  • 36. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic.
    Abu-Raya B; Gantt S; Sadarangani M
    CMAJ; 2020 Aug; 192(34):E982-E985. PubMed ID: 32646869
    [No Abstract]   [Full Text] [Related]  

  • 39. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection.
    Batty CJ; Heise MT; Bachelder EM; Ainslie KM
    Adv Drug Deliv Rev; 2021 Feb; 169():168-189. PubMed ID: 33316346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should the COVID-19 lockdown be relaxed or intensified in case a vaccine becomes available?
    Buratto A; Muttoni M; Wrzaczek S; Freiberger M
    PLoS One; 2022; 17(9):e0273557. PubMed ID: 36054113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.